DefEYE, a company focused on delivering a portfolio of decellularized ocular biologic solutions for the treatment and management of various conditions, including ocular surface diseases, announced in a press release a seed funding round from ExSight Ventures.

According to DefEYE, this funding will enable the company to accelerate commercialization through continued growth and expansion. 

“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE,” says Rob Sambursky, MD, chief executive officer of DefEYE, Inc., in the press release. “Their investment represents a strong validation of our vision to redefine ocular biologics through decellularized placental-based technology. Together, we are positioned to accelerate the adoption of regenerative therapies that elevate the clinical management of both ocular surface disease and ocular surgery.” OM